Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald de Wit

Showing results (91-100 of 175) with videos related to

Pageof 18
Sort By:
BJU International|August 30, 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failureHielke J Meulenbeld, Jean P Bleuse, Elio M Vinci, et al.
European Urology Oncology|November 4, 2023
Early Identification of Patients at Risk of Cabazitaxel-induced Severe NeutropeniaBram C Agema, Stefan A J Buck, Mano Viskil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2003
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study GroupPaul J Hesketh, Steven M Grunberg, Richard J Gralla, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
Health and Quality of Life Outcomes|May 12, 2017
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancerMarieke van Leeuwen, Jacobien M Kieffer, Fabio Efficace, et al.
European Urology Oncology|April 29, 2025
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort AnalysisDebbie G J Robbrecht, Youssra Salhi, John W M Martens, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
JCO Precision Oncology|December 7, 2023
Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate CancerAnouk C de Jong, Khrystany T Isebia, Sui Wai Ling, et al.
British Journal of Cancer|September 29, 2020
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancerLisanne Mout, Jan M Moll, Mingqing Chen, et al.
Pageof 18

Showing results (91-100 of 175) with videos related to

Sort By:
Pageof 18
BJU International|August 30, 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failureHielke J Meulenbeld, Jean P Bleuse, Elio M Vinci, et al.
European Urology Oncology|November 4, 2023
Early Identification of Patients at Risk of Cabazitaxel-induced Severe NeutropeniaBram C Agema, Stefan A J Buck, Mano Viskil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2003
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study GroupPaul J Hesketh, Steven M Grunberg, Richard J Gralla, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987Joaquim Bellmunt, Hans von der Maase, Graham M Mead, et al.
Health and Quality of Life Outcomes|May 12, 2017
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancerMarieke van Leeuwen, Jacobien M Kieffer, Fabio Efficace, et al.
European Urology Oncology|April 29, 2025
Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort AnalysisDebbie G J Robbrecht, Youssra Salhi, John W M Martens, et al.
BMC Cancer|July 25, 2024
Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 studyAndrea Necchi, Michiel S Van der Heijden, Dmytro Trukhin, et al.
JCO Precision Oncology|December 7, 2023
Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate CancerAnouk C de Jong, Khrystany T Isebia, Sui Wai Ling, et al.
British Journal of Cancer|September 29, 2020
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancerLisanne Mout, Jan M Moll, Mingqing Chen, et al.
Pageof 18